WeightWatchers said on Tuesday it would offer compounded form of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares up 13% in early trading. Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's Zepbound,

WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy.

WW International ( NASDAQ: WW ), more commonly known as WeightWatchers, will now offer compounded semaglutide to its WeightWatchers Clinic members, expanding the accessibility of popular weight loss medications to its members at a more affordable price.

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of its weight-management programs, sending its shares nearly 47% higher to an over two-month closing high.

Key Takeaways Shares of WW International, better known as WeightWatchers, soared Tuesday after it said it is offering copycat weight-loss drugs to its members.The compounded treatments will contain the same active ingredient as Novo Nordisk's weight-loss medicines.

Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and will not be covered by social security. FRANCE 24's Sharon Gaffney speaks to Adam Collins,

Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and will not be covered by social security. The main molecule in the medication is also found in the diabetes drug Ozempic which many celebrities have admitted to using to lose weight.